'The completion of this spinoff is a significant achievement for both BD and embecta,' said
The spinoff of embecta demonstrates BD's ongoing commitment to the company's BD 2025 strategy, which includes its three strategic pillars of Grow, Simplify and Empower. The strategic rationale for the spinoff was to create two, independent companies with attractive long-term value for BD shareholders and enhanced strategic, operational and financial characteristics. Each company will focus on its core business and product portfolios, with BD maintaining its category leadership positions across its BD Medical, BD Life Sciences and BD Interventional segments.
embecta will focus on building on its solid foundation as the leading producer of diabetes injection devices, investing in both organic and inorganic growth opportunities and improving the lives of people living with diabetes.
Shareholders will receive one share of embecta common stock for every five common shares of BD that they held as of the close of business on
BD retains no ownership interest in embecta, which will begin trading today on the NASDAQ under the symbol EMBC on a 'regular way' basis.
Please visit?investors.bd.com?for additional information regarding the spinoff, including links to filings with the
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Forward-Looking Statements This press release contains certain forward-looking statements (as defined under Federal securities laws) regarding BD and the spinoff of embecta, including the anticipated benefits of the spinoff. All such statements are based upon current expectations of BD and involve a number of risks and uncertainties. With respect to forward-looking statements contained herein, a number of factors could cause actual outcomes to vary materially. These factors include, but are not limited to, risks associated with the impact or terms of the spinoff, as well as other factors discussed in BD's filings and embecta's filings with the
Contact:
Media
VP
Public Relations
T: 858.617.2361
E: troy.kirkpatrick@bd.com
Investors
SVP
Head of Investor Relations
T: 201.847.5743
E: francesca.demartino@bd.com
(C) 2022 Electronic News Publishing, source